Page header

Position of the Transparency Council – Ospolot (sultiam)

At its meeting on 22 August 2022 the Transparency Council adopted Position No.  81/2022 on the legitimacy of granting consent for reimbursement of the medicinal product Ospolot (sulthiame) for the indications: epilepsy, drug-resistant epilepsy, drug-resistant epilepsy in the course of Rett syndrome. 

 

Publication in Public Information Bulletin (BIP)